F10 and hematoma: Indeed, in a recent German retrospective multicenter cohort study authors demonstrated that hemostatic treatment with PCC was not associated with a reduced risk of hematoma enlargement, mortality, or unfavorable functional outcome either in overall DOACS-related ICH or specifically in factor Xa inhibitor–related ICH [47].